Sagimet Biosciences Inc. is a biopharmaceutical company focused on creating treatments for diseases linked to faulty lipid metabolism. Its main project, Denifanstat, targets conditions like nonalcoholic steatohepatitis and acne through the inhibition of fatty acid synthase (FASN). Additionally, Sagimet is working on a drug for various cancers. Originally named 3-V Biosciences, it rebranded in 2019 and operates from San Mateo, California, since its founding in 2006.
Penny stocks are a fascinating category of investment opportunities. While risky, these stocks allow you to invest in companies when they’re young and underdeveloped. So making the right penny stock picks can…
